← All diseases
Cancer
Lung cancer (non-small cell)
Do you want to receive a message when there is new research on Lung cancer (non-small cell)? This is possible with an account. Create a free account or log in.
Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence
Read in plain language what each study is about? With Premium, one sentence appears above each publication explaining what was studied — and you'll be notified as soon as new research about Lung cancer (non-small cell) is available. View what Premium costs.
Publications and studies (3220)
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Will We Need a Novel Heuristic in Resectable Lung Cancer?: A Narrative Review. (2026/04/25) ♡
- Prognostic value of CALLY index in patients with locally advanced non-small cell lung cancer treated with thoracic radiotherapy. (2026/04/24) ♡
- Efficacy and Safety of Acupuncture for Pain in Non-Small Cell Lung Cancer: A Meta-Analysis. (2026/04/21) ♡
- Prognostic value of the Scottish Inflammatory Prognostic Score in advanced NSCLC treated with second-line nivolumab. (2026/04/21) ♡
- Prognostic value of chemotherapy-related mean corpuscular hemoglobin (MCH) kinetics in patients with non-small cell lung cancer receiving adjuvant chemotherapy. (2026/04/21) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Impact of Nutritional Status and Body Composition on Osimertinib Tolerance in Non-Small-Cell Lung Cancer. (2026/04/20) ♡
- A real-world study on the comparative effectiveness of first-line treatment regimens in advanced NSCLC patients with PACC mutations. (2026/04/20) ♡
- Baseline vitamin D status and clinical outcomes in advanced non-small cell lung cancer patients treated with nivolumab. (2026/04/14) ♡
- Association between C-reactive protein-to-albumin ratio and the risk of overall survival in advanced non-small cell lung cancer patients with anlotinib treatment: a retrospective cohort study. (2026/04/11) ♡
- Danggui Buxue Tang, a Traditional Chinese Herbal Formula, Potentiates Paclitaxel Efficacy in Non-Small-Cell Lung Cancer by Inducing Ferroptosis via the Nrf2/GPX4 Axis. (2026/04/10) ♡
- Prognostic nutritional index improved the survival prediction of the revised Tokuhashi and Tomita scores for patients with lung cancer spinal metastases. (2026/04/07) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Development and validation of an inflammatory-immune-nutritional integrated scoring system: a novel strategy for predicting postoperative survival in non-small cell lung cancer. (2026/04/06) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Artificial Intelligence Assisted (18)F-FDG PET Radiomics in Classifying Histological Subtypes of Lung Cancer: Systematic Review and Meta-analysis. (2026/04/01) ♡
- PFKM promotes chemoresistance in lung adenocarcinoma by regulating RAB8B mediated exosome release. (2026/04/01) ♡
- Exploration of Mechanisms of Keliu Pill on the Inhibition of Lymphangiogenesis in Non-small Cell Lung Cancer Based on Network Pharmacology and Experimental Validation. (2026/04/01) ♡
- AANG: A natural compound formulation for targeting macrophage-myofibroblast transition in non-small-cell lung carcinoma. (2026/04/01) ♡
- Integrating network pharmacology and Mendelian randomization to explore potential targets of Fufang Banmao capsule against non-small cell lung cancer. (2026/04/01) ♡
- [Evidence mapping analysis of clinical studies on Chinese patent medicines for non-small cell lung cancer from past five years]. (2026/04/01) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. A clinic-responder-derived defined microbial consortium enhances anti-PD-1 immunotherapy efficacy in mice. (2026/04/01) ♡
- Undetected Weight Loss Associates With Upstaging in Cancer Patients. (2026/04/01) ♡
- Using the Systemic Inflammatory Response Index and the Prognostic Nutritional Index in Predicting Subsequent Bone Metastases in Patients with Non-Small Cell Lung Cancer. (2026/04/01) ♡
- Identification of Hidden Cachexia Subgroup in PD-L1-High NSCLC: Comparative Analysis of the AWGC vs. Fearon Criteria. (2026/04/01) ♡
- Clinical determinants and biomarkers for predicting chemotherapeutic response in advanced non-small cell lung cancer: a single-center retrospective study. (2026/04/01) ♡
- [Buzhong Yiqi Decoction induces ferroptosis of A549/DDP cells to reverse cisplatin resistance in non-small cell lung cancer via AMPK/ACC1 signaling pathway]. (2026/04/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Multiple Endocrine Neoplasia Type I. (2026/03/28) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Multiple Endocrine Neoplasia Type I. (2026/03/28) ♡
- The Association Between Inflammatory Scores and Frailty Severity: An Exploratory Retrospective Analysis in Non-Small-Cell Lung Cancer Surgical Patients. (2026/03/28) ♡
- Integrated pharmacokinetic properties, tissue distribution and metabolism of multiple active constituents in DBD for the treatment of GEM-induced myelosuppression. (2026/03/25) ♡
- Monocyte Preprogramming by Tobacco Carcinogens and Fructose Intake Accelerates Lung Cancer Progression via Metabolic and Epigenetic Pathways. (2026/03/25) ♡
- Predictive value of the systemic immune-inflammation index and geriatric nutritional risk index on the efficacy of immunotherapy and survival prognosis in advanced non-small cell lung cancer: a retrospective study. (2026/03/25) ♡
- [Shengmai San improves osimertinib resistance of non-small cell lung cancer cells by regulating the lactate/Wnt/β-catenin/LDHA pathway]. (2026/03/20) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Medicinal Plant Seeds in Nutritional Oncology: An Integrative Review of Emerging Therapeutics for Non-Small Cell Lung Cancer. (2026/03/20) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. A prospective study on the predictive value of the modified Glasgow prognostic score in non-small cell lung cancer treated with radiation therapy. (2026/03/19) ♡
- Prognostic value of the C-reactive protein-albumin-lymphocyte (CALLY) index in surgically treated non-small cell lung cancer. (2026/03/19) ♡
- The prognostic impact of tryptophan on non-small cell lung cancer survival: insights from plasma essential amino acids. (2026/03/16) ♡
- Impact of proton pump inhibitors on immunotherapy is modulated by prior chemotherapy and linked to gut microbiome-immune cell signatures. (2026/03/09) ♡
- Treatment patterns, and outcomes in elderly patients with metastatic non-small cell lung cancer: a real-world analysis from a single center in China. (2026/03/02) ♡
- Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC. (2026/03/01) ♡
- Wedge resection versus segmentectomy for older patients with stage IA non-small cell lung cancer. (2026/03/01) ♡
- An integrated analysis of network pharmacology and GEO database to decode the active component and the underlying mechanism of Yiwei decoction in non-small cell lung cancer. (2026/03/01) ♡
- Five-year survival of patients with non-small cell lung cancer treated with alkalization therapy. (2026/03/01) ♡
- Evaluation of inflammatory parameters and ferritin as prognostic factors in non-small cell lung cancer patients receiving nivolumab immunotherapy. (2026/03/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Sex Differences in Cancer Immunotherapy-Clinical Evidence and Mechanisms With a Focus on NSCLC. (2026/03/01) ♡
- Modulatory Effects of Cirsimarin on Lung Cancer A549 Cells Migration in 2D and 3D Cultures Involves Transcriptional Regulation of Metalloproteinases. (2026/03/01) ♡
- Adjuvant chemotherapy appears less effective in undernourished lung cancer patients as assessed by the controlling nutritional status score: a retrospective cohort study. (2026/02/28) ♡
- Deciphering immune heterogeneity in lung adenocarcinoma via machine learning-based Differential Phenotype Immune Score: TPX2 as a key biomarker for immunotherapy resistance. (2026/02/27) ♡
- Specific depletion of TIGIT(high) CD226(-) clonally expanded intratumoral Tregs defines safe and effective TIGIT targeting. (2026/02/24) ♡
- Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. [Huangqi Guizhi Wuwu Decoction in the Treatment of Pemetrexed Intrathecal Chemotherapy-induced Neurotoxicity in NSCLC Patients with Leptomeningeal Metastases: A Randomized Controlled Trial]. (2026/02/20) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Stage IIIB ROS1-Positive NSCLC management: crizotinib + surgery + TCM achieves exceptionally prolonged PFS (a case report). (2026/02/16) ♡
- Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. Comparative efficacy of trastuzumab deruxtecan versus guideline-recommended treatments for 2L+ unresectable locally advanced or metastatic HER2-mutant non-small cell lung cancer: a systematic review and indirect treatment comparison. (2026/02/13) ♡
codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.